Wire · opportunities
Ozempic, Wegovy get new rivals as Kenya approves seven Semaglutide drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 August 2026 · Fusion42 review
Kenya's drug regulator has approved seven semaglutide products, including generics, expanding treatment options for type 2 diabetes and weight management amid rising obesity and diabetes cases. The approvals include different indications restricting interchangeability, and the regulator warns against off-label use and black market purchases.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Your diabetes and weight management therapies now face incoming competition from multiple generics approved in Kenya, not all interchangeable with original drugs. Lock in healthcare providers who understand these distinctions to avoid losing patients using black market or off-label alternatives.
◆ Coverage
1 source · 14 Aug 2026
◆ Related on Wire
◆ Topics